Sales growth driven by continued strong performance from Kisqali (+64% cc), Entresto (+22% cc), Kesimpta (+33% cc), Scemblix (+79% cc), Leqvio (+61% cc) and Pluvicto (+30% cc) Core operating income ...

Novartis has inked a deal with Sironax that gives the pharma the exclusive option to acquire the biotech’s blood-brain ...

Sironax, a clinical-stage biotech company dedicated to the discovery and development of transformational therapies for age-related diseases, today announced a strategic agreement with Novartis under ...

Swiss drugmaker Novartis will keep making medicines for malaria and leprosy, even if it does not get orders as normal amid the global health funding crunch, its president of global health told ...

Novartis is thriving with double-digit growth, driven by key drugs in oncology, cardiology, immunology, and neurology. See why NVS stock earns a buy rating.

Novartis has agreed to buy Regulus Therapeutics for up to $1.7 billion, giving the Swiss drugmaker access to an experimental drug to treat a life-threatening kidney disease.

Novartis AG has agreed to buy U.S. biotech firm Regulus Therapeutics Inc. in a deal that could be valued at up to $1.7 billion.

European drugmaker Novartis (NVS), best known for blockbuster drugs like Entresto, Cosentyx, and Kesimpta, just announced a major U.S. investment. The $200 billion pharma company intends to invest ...

Novartis stock popped Thursday — prompting Travere Therapeutics to slide — after winning FDA approval for a kidney disease treatment.

Novartis NOVN 1.36% has agreed to acquire Regulus Therapeutics for a total equity value of up to roughly $1.7 billion. With the merger, the Swiss pharmaceutical company aims to bring to more ...

Fortune 500 pharmaceutical company Novartis has agreed to acquire San Diego-based Regulus Therapeutics in a deal potentially worth $1.7 billion. (Novartis) ...

Novartis is getting global rights to a Monte Rosa Therapeutic molecular glue degrader drug in early clinical testing as a potential treatment for autoimmune disorders. The deal comes months after ...